Perindopril versus Angiotensin II Receptor Blockade in Hypertension and Coronary Artery Disease
- 34 Downloads
The renin-angiotensin-aldosterone system (RAAS) is now known to play a key role in the pathogenesis of hypertension and a range of other cardiovascular diseases. Two groups of drugs, the ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) have been developed with the aim of improving clinical outcomes by regulating the RAAS in patients with cardiovascular disease.
Initial assumptions were that these two drug types might be interchangeable, but ongoing research has revealed differences between them in terms of pharmacology and outcomes in clinical trials. Although both groups of drugs lower blood pressure, studies of the ACE inhibitor perindopril have revealed preservation of beneficial vascular and endothelial effects mediated by bradykinin and nitric oxide. The selective blockade exerted by ARBs is not associated with these effects. Furthermore, examination of clinical endpoints in major clinical trials has provoked discussion about outcomes comparing ACE inhibitors and ARBs, with recent debate focusing on the incidence of myocardial infarction (MI) in patients receiving these agents. Whether there is an actual difference in protection from MI remains unresolved, although available data confirm the benefit and safety of ACE inhibitors, in particular perindopril, for myocardial protection.
KeywordsLosartan Amlodipine Bradykinin Valsartan Telmisartan
Preparation of this manuscript was supported by Servier. Editorial assistance was provided by WK Health Medical Communications.
- 16.Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group: effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial —Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–60PubMedCrossRefGoogle Scholar
- 20.Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees: effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors —the CHARM-Alternative trial. Lancet 2003; 362: 772–6PubMedCrossRefGoogle Scholar
- 21.McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees: effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors —the CHARM-Added trial. Lancet 2003; 362: 767–71PubMedCrossRefGoogle Scholar
- 26.Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond) 1994; 87: 567–74Google Scholar
- 28.EUROPA Investigators. The European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators: efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease —randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8CrossRefGoogle Scholar
- 29.Ferrari R. PERTINENT: PERindopril, Thrombosis, InflammatioN, Endothelial dysfunction and Neurohormonal activation Trial, a sub-analysis of EUROPA [abstract 2585]. Annual Congress of the European Society of Cardiology. 2004; Aug 28–Sep 1: Munich, GermanyGoogle Scholar
- 39.Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators: effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome —results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med 2006; 166: 659–66PubMedCrossRefGoogle Scholar
- 43.Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required plus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906PubMedCrossRefGoogle Scholar
- 47.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97CrossRefGoogle Scholar
- 50.Gupta AK. Determinants of new onset diabetes among hypertensive patients randomized in the ASCOT-BPLA trial [abstract]. World Congress of Cardiology; 2006 Sep 2–6, BarcelonaGoogle Scholar
- 59.Turnbull F. New evidence of blood pressure-independent effects for agents acting via the renin-angiotensin system: analyses from the Blood Pressure Lowering Treatment Trialists’ Collaboration [abstract]. Program and abstracts from the Fifteenth European Meeting on Hypertension, June 17–21, 2005, Milan, ItalyGoogle Scholar
- 62.National Institute for Health and Clinical Excellence (NICE). Hypertension: management of hypertension in adults in primary care (partial update). NICE guideline: draft for consultation. London: February 2006 [online]. Available from URL: http://www.nice.org.uk/pdf/Hypertension_update_NICE_0206.pdf [Accessed 2006 Nov 17]
- 63.National Institute for Clinical Excellence (NICE). Hypertension: management of hypertension in adults in primary care. Clinical guideline 18. London: August 2004 [online]. Available from URL: http://www.nice.org.uk/pdf/CG018fullguideline.pdf [Accessed 2006 Nov 17]
- 64.US Dept of Health and Human Services. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. National Institutes of Health, National Heart, Lung, and Blood Institute National High Blood pressure Education Program. NIH Publication No. 04-5230, August 2004 [online]. Available from URL: http://www.nhbli.nih.gov/guidelines/hypertension/jnc7full.pdf [Accessed 2006 Nov 17]
- 65.PROGRESS Collaborative Group. Effects of a perindoprilbased blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475–84Google Scholar